Financial Consulate’s Vir Biotechnology VIR Stock Holding History

Financial Consulate’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$112	Buy	+10	New	+$100	﹤0.01%	1796

Other funds holding VIR

Y-Intercept (HK) Hong Kong $4.52B AUM 6.6% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.56B AUM 41.43% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return

Amalgamated Bank New York $14.3B AUM 35.81% 1-Year Est. Return

Yousif Capital Management Bloomfield Hills, Michigan $8.87B AUM 34.1% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Atria Investments Charlotte, North Carolina $10.3B AUM 19.62% 1-Year Est. Return

Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return

Financial Consulate's VIR Position: Q3 2026 in Review

Financial Consulate opened a new position in Vir Biotechnology (VIR) in Q3 2026: 10 shares worth $112. The stake represents ﹤0.01% of the portfolio and ranks #1796 among its holdings.

37 funds tracked by Wall St. Rank hold VIR as of Q3 2026.

Financial Consulate held 10 shares of Vir Biotechnology worth $112 as of Q3 2026.
Vir Biotechnology was a new Financial Consulate position in Q3 2026.
Vir Biotechnology made up ﹤0.01% of Financial Consulate's portfolio in Q3 2026, its #1796 holding.
37 funds tracked by Wall St. Rank held Vir Biotechnology as of Q3 2026.

Based on Financial Consulate's 13F filing for Q3 2026, filed 23 Oct 2026.